NCT06544928

Study on Home Obstructive Respiratory Exacerbations

Enrolling by Invitation
Not specifiedAges 40–80Observational
Strados Labs, Inc.
~20 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:RESP™ Biosensor

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The study will assess observational outcome measures. No formal efficacy or safety endpoints are defined.
Measured over 12 months
COPD Exacerbation
COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection
COPD Exacerbation Acute
COPD
1 sites across 1 states
Pennsylvania1

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hospitalized for COPD exacerbation with plan for discharge within 48 hours OR
Visiting pulmonologist post COPD-exacerbation within 14 days of discharge from hospital 3. Tobacco History: Current or Former Smoker
Has smoked at least 100 cigarettes in his/her lifetime 4. Patient can follow study procedures, including instructions for self-placement and operation of biosensor
Patient has experience/owns a smartphone 5. Patient is accessible by telehealth/telephone for duration of the study 6. Patient is able and willing to return to study site for study visits as necessary
  • The study will assess observational outcome measures. No formal efficacy or safety endpoints are defined.12 months